CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Type 2 diabetes mellitus

Glycemic & MetabolicDisease / conditionriskmodifiablegenetic-causal
88
evidence score

Also known as: Diabetes, Diabetes mellitus, Diabetes mellitus (DM), Type 2 diabetes, Type-2 diabetes, diabetes, diabetes mellitus, diabetics, history of diabetes, t2dm, type 2 diabetes, type 2 diabetes (T2D)

PREVENT status

✓ Used by PREVENT (core input).

Also used by the Pooled Cohort Equations.

Causal support

genetic causal candidate

Score components
lit volume: 30meta-analyses: 20trials: 15genetic: 12.6MR bonus:
Associated genes
TCF7L2

References (1408)

98 meta-analyses / systematic reviews

Clinical trials (746)

showing top 60
NCTTitleStatusTypeInterventions
NCT07172971duCHennE caRdiomyopathy mItigation Sglt2 inHibitorRECRUITINGINTERVENTIONALSGLT-2 inhibitor, SGLT2 inhibitor
NCT07572032DELayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected aetiologY (DELAY-HF), Pilot StudyRECRUITINGINTERVENTIONALSacubitril / Valsartan, SGLT-2 inhibitor, Sacubitril / Valsartan
NCT07284511Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialRECRUITINGINTERVENTIONALTirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting
NCT07578584Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Weekly Doses of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and in Participants With Type 1 Diabetes With Overweight or ObesityRECRUITINGINTERVENTIONALNNC0497-0040, Placebo
NCT07221214GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCTRECRUITINGINTERVENTIONALSemaglutide (Rybelsus®), Placebo
NCT07175051Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, EmpagliflozinRECRUITINGINTERVENTIONALEmpagliflozin (oral)
NCT07491042Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients: A Six-month Prospective .StudyRECRUITINGINTERVENTIONALDapagliflozin
NCT07359105A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy for Primary Prevention of Cardiovascular Events in Patients 70 Years of Age or Older With Type 2 Diabetes (iTARGET-Elderly Study)RECRUITINGINTERVENTIONALModerate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
NCT07588256New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAMRECRUITINGINTERVENTIONALInteractive digital modules, Antihypertensive Medication Management
NCT07198789Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial to Evaluate the Effect of a Functional Low-Glycemic Index Carbohydrates Versus Standard Wholegrain Carbohydrates on Glycolipid Metabolism and Vascular Stress Markers in Subjects With Suboptimal TriglyceridemiaRECRUITINGINTERVENTIONALAltograno® Bakery Foods, Standard Whole-Grain Bakery Foods
NCT07246421Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 DiabetesRECRUITINGINTERVENTIONALGlugagon
NCT07027995Food and Fitness With MedicineRECRUITINGINTERVENTIONALExercise is Medicine (EIM), Culinary Education, Food is Medicine
NCT07214818Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled TrialRECRUITINGINTERVENTIONALDapagliflozin, Empagliflozin, Standard Therapy
NCT06966258Inspire HER: Inspiring the Heart and Emotions for Radical HealthRECRUITINGINTERVENTIONALInspire HER Intervention
NCT07403669Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical TrialRECRUITINGINTERVENTIONALCHAPERONE AI, CKMiq AI, Quality of Life
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT06745544Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes: Protocol for a Randomized Control Trial: DIACTIVERECRUITINGINTERVENTIONALRhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)
NCT07143773SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Double-blind, Placebo Controlled, National, Multicenter TrialRECRUITINGINTERVENTIONALSGLT-2 inhibitor, Placebo
NCT07091500Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With ObesityRECRUITINGINTERVENTIONALExercise training, Semaglutide, Therapy Cessation
NCT07124923Effectiveness of a Continuous Care Intervention by the Endocrinology and Nutrition Service in Primary Care to Improve the Control of Type 2 Diabetes Mellitus in Terres de l'Ebre, CataloniaRECRUITINGINTERVENTIONALContinuity-of-Care intervention
NCT06609356Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesRECRUITINGINTERVENTIONALStudy Visit 1, Placebo, Study Visit 2
NCT06762964Cardiac and Metabolic Effects of Dapagliflozin in the Failing Fontan Circulation: A Phase II, Prospective, Double-Blind StudyRECRUITINGINTERVENTIONALDapagliflozin tablet, Placebo Tablet
NCT07045623Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes PatientsRECRUITINGINTERVENTIONALcentralized management and education group
NCT07244003Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic ControlRECRUITINGINTERVENTIONALMetformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin
NCT06887062Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)RECRUITINGINTERVENTIONALBosentan and dapagliflozin
NCT07482020A Randomized Controlled Trial of SGLT2 Inhibitors to Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation and Comorbid Hypertension and Abnormal Glucose MetabolismRECRUITINGINTERVENTIONALSGLT-2 inhibitors, Placebo
NCT06593327Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes MellitusRECRUITINGINTERVENTIONALIntensive Prevention Strategy
NCT07614659Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older AdultsRECRUITINGINTERVENTIONALHome-based multimodal cardiovascular screening
NCT07245069Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer PatientsRECRUITINGINTERVENTIONALDapagliflozin 10 mg, Placebo
NCT06435156A Phase 2 Double-blind Randomised Controlled Trial Studying the Effect of Sotagliflozin Versus Placebo in Individuals With Heart Failure and Type 1 Diabetes.RECRUITINGINTERVENTIONALSotagliflozin, Placebo
NCT06562582STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical TriaRECRUITINGINTERVENTIONALBisoprolol Oral Tablet, Ramipril Oral Product, Dapagliflozin Oral Product
NCT06693934Jockey Club Precision Prevention Programme on Young Onset DiabetesRECRUITINGINTERVENTIONALRisk assessment with biogenetic and clinical test to predict diabetes risk, Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors, Medication
NCT06528405The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRECRUITINGINTERVENTIONALdapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin
NCT06396416Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)RECRUITINGINTERVENTIONALSemaglutide, Virtual Weight Management Coaching
NCT06446531Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsRECRUITINGINTERVENTIONALPlacebo, Rybelsus Tablet, Jardiance 25Mg Tablet
NCT06435858Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney DiseaseRECRUITINGINTERVENTIONALEmpagliflozin, Placebo
NCT06535529Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure PatientsRECRUITINGINTERVENTIONALAcetazolamide, Dapagliflozin 10mg
NCT06436326The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural FactorsRECRUITINGINTERVENTIONALContinuous glucose monitor, Perinatal nursing care for gestational diabetes, Blood glucose meters (BGM)
NCT07447362Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After StudyRECRUITINGINTERVENTIONALStructured Cardiovascular Risk Management
NCT06024746Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)RECRUITINGINTERVENTIONALFinerenone, Empagliflozin
NCT06082063Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRECRUITINGINTERVENTIONALAspirin tablet, Semaglutide, Sotagliflozin
NCT06304857A Multicentre, Randomised, Double-blind, Placebo-controlled Phase III Study, Evaluating the Effect of Dapagliflozin on Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Anthracycline-based ChemotherapyRECRUITINGINTERVENTIONALDapagliflozin, Placebo
NCT06775028AFFIRMO - Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older PeopleRECRUITINGINTERVENTIONALiABC platform use
NCT05852704SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative Atrial Fibrillation and Kidney Injury (STENOTYPE Trial)RECRUITINGINTERVENTIONALDapagliflozin 10mg Tab, Placebo Tab
NCT06112418A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular EventsRECRUITINGINTERVENTIONALThe Cleerly CAD Staging System
NCT05786443A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney DiseaseRECRUITINGINTERVENTIONALEmpagliflozin 10 MG, Placebo
NCT05780905Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesRECRUITINGINTERVENTIONALSemaglutide Auto-Injector, Placebo
NCT06291155Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney DiseaseRECRUITINGINTERVENTIONALSGLT2 inhibitor
NCT06163768Effects of Insulin Resistance in Non-diabetic Acute Coronary Syndrome Patients by the Homeostasis Model Assessment Index (HOMA2-IR)RECRUITINGINTERVENTIONALInsulin resistance
NCT05987410EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Diabetic patiEnts With Cardiovascular Disease. The VENERE StudyRECRUITINGINTERVENTIONALNordic Walking (NW), Standard Rehabilitation (SR), Cardiological Counselling (CC)
NCT06060392Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-LitRECRUITINGINTERVENTIONALSemaglutide Pill
NCT06055036Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health InterventionRECRUITINGINTERVENTIONALBlack Impact Intervention
NCT05986136Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel DiseaseRECRUITINGINTERVENTIONALMesalamine, Dapagliflozin 10mg Tab
NCT05766735Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle ModificationRECRUITINGINTERVENTIONALRoutine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC)
NCT05819138Type 1 Diabetes Impacts of Semaglutide on Cardiovascular OutcomesRECRUITINGINTERVENTIONALSemaglutide Pen Injector, Placebo
NCT05844644An Open Label Study Evaluating the Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 DiabetesRECRUITINGINTERVENTIONALRelease
NCT02915198CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)RECRUITINGINTERVENTIONALMetformin XR, Placebo
NCT05757791A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive DisorderRECRUITINGINTERVENTIONALEmpagliflozin
NCT07272343A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular MechanismsRECRUITINGINTERVENTIONALsemaglutide, caloric restriction
NCT05431296Glucose Monitoring After Acute Myocardial Infarct in People With DiabetesRECRUITINGINTERVENTIONALDexcom ONE Continuous Glucose Monitoring System

Genetic associations (17)

VariantGene(s)TraitpOR/βStudy
rs35519679TCF7L2coronary artery disorder1e-218—GCST90451699
rs34872471TCF7L2coronary artery disorder1e-400.173769 increaseGCST90274723
rs142827301TCF7L2coronary artery disorder1e-270.159503 increaseGCST90274723
rs4506565TCF7L2stroke disorder1e-17—GCST004045
rs35519679TCF7L2stroke disorder1e-160.114813 increaseGCST90274723
rs753617426TCF7L2stroke disorder1e-150.0959287 increaseGCST90274723
rs7903146TCF7L2atherosclerosis1e-130.1759 unit decreaseGCST90480196
rs7903146TCF7L2peripheral arterial disease1e-111.06GCST008474
rs7903146TCF7L2atherosclerosis1e-110.07749 unit decreaseGCST90480198
rs11196175TCF7L2stroke disorder1e-100.086168 increaseGCST90274723
rs61872790TCF7L2stroke disorder1e-100.106283 increaseGCST90274723
rs11196180TCF7L2stroke disorder1e-100.0779135 increaseGCST90274723
rs7903146TCF7L2peripheral arterial disease1e-101.06GCST90061371
rs4506565TCF7L2stroke disorder1e-9—GCST004044
rs11196288TCF7L2, RNU7-165PIschemic stroke1e-81.41GCST003324
rs7903146TCF7L2abdominal aortic aneurysm1e-80.0481 unit decreaseGCST90432152
rs499832TCF7L2, RNU7-165Pperipheral arterial disease1e-76.66GCST004482